The HPV 9-10 Trial: Early Initiation of HPV Vaccination

Launched by UNIVERSITY OF COLORADO, DENVER · Jan 22, 2021

Keywords

ClinConnect Summary

The HPV 9-10 Trial is studying whether giving the HPV vaccine to children at younger ages, specifically 9 to 10 years old, can help more kids get vaccinated before they start sexual activity. Currently, the vaccine is recommended at ages 11 or 12, but many parents hesitate to vaccinate their children. By starting the vaccination process earlier, the researchers hope to see an increase in the number of children who are fully vaccinated, which can prevent certain cancers caused by the human papillomavirus (HPV).

To participate in this trial, children must be between 9 and 13 years old, and their medical practices must be located in Metro Denver, Colorado or Metro Los Angeles, California. The practices involved should currently not recommend the HPV vaccine for 9-10 year-olds and must have at least 100 eligible patients in that age range. If selected, families can expect to be part of a study that aims to improve vaccination rates and ultimately protect children from HPV-related cancers.

Gender

ALL

Eligibility criteria

• Practices:
• Inclusion Criteria:
• • Practices in Metro Denver, Colorado and Metro Los Angeles, California (specifically UCLA medical clinics and clinics affiliated with Children's Hospital of Orange County)
• • Practices that have at least 60% of providers agree to participate
• • Practices do not currently recommend HPV at 9-10 years.
• • Practice must have at least 100 eligible patients age 9-13 years
• Exclusion Criteria:
• • Practices with less than 100 eligible patients age 9-13 years
• • Practices currently routinely recommend HPV vaccine at 9-10 years.
• • Practices where less than 60% of providers agree to participate in the study.
• • Patients whose data will be used to assess the outcomes of the intervention will be age 9-13 years old.